Stock

CNTA

CENTESSA PHARMACEUTICALS PLC

Latest close $407 of 27 marquee funds currently hold1 CUSIP mapped

Current holders

27 funds tracked

Ever held

Current + past

New this quarter

Exited this quarter

Marquee-fund ownership over time

Aug 9, 2024Feb 14, 2025Feb 13, 2026May 15, 2026

Now

This quarter's activity

New positions opened

Point72 Asset Management
Q2 2026 · 307,355 shares
+$12.18M

Positions exited

None.

Current holders

Sorted by tenure (longest first)

Fund	First disclosed	Held	Entry price	Latest close	Return on entry
Renaissance Technologies	Q3 2024(8Q snapshot)	7Q	$11	$40	+259%
Citadel Advisors re-entered	Q3 2024(8Q snapshot)	7Q	$13	$40	+215%
Two Sigma Investments	Q3 2024(8Q snapshot)	7Q	$13	$40	+215%
Millennium Management	Q3 2024(8Q snapshot)	7Q	$13	$40	+215%
Point72 Asset Management re-entered	Q3 2024(8Q snapshot)	7Q	$13	$40	+215%
D.E. Shaw re-entered	Q4 2024(8Q snapshot)	6Q	$18	$40	+127%
Maverick Capital	Q1 2026	1Q	$25	$40	+60%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Centessa Pharmaceuticals plc. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d

Filings · last 90d

Total on file

270

Recent SEC buffer

Most recent

May 18, 2026

30d / 90d windows measured from May 18, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 270 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · CENTESSA PHARMACEUTICALS PLC

Annual figures sourced directly from CENTESSA PHARMACEUTICALS PLC's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue

$15M

FY2025

Net income

-$197.53M

FY2025+16% YoY

EPS (diluted)

$-1.46

FY2025+29% YoY

Free cash flow(?)

-$194.19M

FY2025-37% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Centessa Pharmaceuticals plc — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds

Fund	Open date	Close date	Open price	Close price / current	Return
Point72 Asset Management	Q2 2026	open	$40	$40	+0%
Maverick Capital	Q1 2026	open	$25	$40	+62%
Citadel Advisors	Q4 2025	open	$28	$40	+44%
D.E. Shaw	Q3 2025	open	$18	$40	+125%
D.E. Shaw	Q4 2024	Q1 2025	$18	$17	-2%
Citadel Advisors	Q3 2024	Q3 2025	$13	$18	+40%
Two Sigma Investments	Q3 2024	open	$13	$40	+215%
Millennium Management	Q3 2024	open	$13	$40	+215%
Point72 Asset Management	Q3 2024	Q1 2026	$13	$25	+98%
Renaissance Technologies	Q3 2024	open	$11	$40	+259%

Caveats

Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
“Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.